INTRADERMAL STUDY OF A NEW LOCAL ANAESTHETIC AGENT: aptocaine (cas 19281-29-9)

Add time:07/31/2019    Source:sciencedirect.com

SUMMARYIn a double-blind trial in 28 human volunteers, a new local anaesthetic agent, aptocaine, was compared intradermally at 1, 2 and 3% concentrations with lignocaine 2% and bupivacaine 0.5%. In a second trial in 27 subjects, 1% aptocaine was compared with mepivacaine and prilocaine, both 1, 2 and 3 %. In terms of activity as determined by area of anaesthesia, and of duration of action, aptocaine was similar to mepivacaine and more active and long-lasting than lignocaine and prilocaine. By this route aptocaine also appeared longer-lasting than bupivacaine. Duration of action was unaffected by concentration. Aptocaine had marked vasoconstrictor activity, which was maximal at 1%. These local anaesthetic properties suggest that aptocaine merits clinical trials, especially in dentistry.

We also recommend Trading Suppliers and Manufacturers of aptocaine (cas 19281-29-9). Pls Click Website Link as below: cas 19281-29-9 suppliers

Prev:Synthesis, anticancer and antioxidant activities of 2,4,5-trimethoxy chalcones and analogues from asaronaldehyde: Structure–activity relationship
Next:Synthesis of urea analogues bearing N-alkyl-N'-(thiophen-2-yl) scaffold and evaluation of their innate immune response to toll-like receptors)